Needle bleb revision of encapsulated filtering bleb with bevacizumab

Ophthalmic Surgery Lasers and Imaging

Volumn 37, Issue 2, 2006, Pages 147-150

  Kahook, Malik Y ^a,b   Schuman, Joel S ^a   Noecker, Robert J ^a  

^a University of Pittsburgh School of Medicine   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; GATIFLOXACIN; MITOMYCIN C; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CASE REPORT; FILTERING OPERATION; HUMAN; MALE; NEEDLE; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; RISK FACTOR; TRABECULECTOMY; VISUAL ACUITY; BLISTER; CONJUNCTIVA; DRUG EFFECT; FOLLOW UP; GLAUCOMA; INJECTION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; REOPERATION; TREATMENT FAILURE; VASCULARIZATION;

ANTIBODIES, MONOCLONAL; BLISTER; COMBINED MODALITY THERAPY; CONJUNCTIVA; FOLLOW-UP STUDIES; GLAUCOMA; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; OCULAR HYPERTENSION; REOPERATION; TRABECULECTOMY; TREATMENT FAILURE;

EID: 33645528757     PISSN: 15428877     EISSN: None     Source Type: Journal    
DOI: 10.3928/1542-8877-20060301-12     Document Type: Article

References (11)

1. Funatsu H, Yamashita H, Sakata K, et al. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology. 2005;112:806-816.
2. Campochiaro PA, Soloway P, Ryan SJ, Miller JW. The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration. Mol Vis. 1999;5:34.
3. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60-65.
4. Reichel E. Intravitreal bevacizumab for choroidal neovascularization and cystoid macular edema: a cost-effective treatment? Ophthalmic Surg Lasers Imaging. 2005;36:270-271.
5. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331-335.
6. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005;36:336-339.
7. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035-1047.
8. Wong J, Wang N, Miller JW, Schuman JS. Modulation of human fibroblast activity by selected angiogenesis inhibitors. Exp Eye Res. 1994;58:439-451.
9. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267:10931-10934.
10. Asahara T, Bauters C, Zheng LP, et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation. 1995;92(9 Suppl):II365-II371.
11. Seghezzi G, Patel S, Ren CJ, et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol. 1998;141:1659-1673.